Potential Utility of Cannabidiol in Stress-Related Disorders.
Nicole A Lookfong, Wesley M Raup-Konsavage, Yuval Silberman
Cannabis and Cannabinoid Research April 2023 DOI: 10.1089/can.2022.0130 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Cannabidiol (CBD) |
| Topics | CBD Neuroplasticity PTSD |
| Keywords | Childhood trauma |
| Key findings | The authors conclude that preclinical evidence supports CBD as a potential treatment for stress and anxiety disorders arising from prior stressful events, particularly by reducing fearful behavior and promoting extinction of contextual fear memories, which are hallmarks of PTSD. They note that very limited clinical research has tested CBD for this purpose and that further study is needed, while cautioning that THC-containing cannabinoid products may exacerbate stress-related behaviors. |
Abstract
Background: The endocannabinoid (eCB) system plays an important role in homeostatic regulation of anxiety and stress responses; however, the eCB system can be disrupted following traumatic stressors. Additionally, traumatic or chronic stressors that occur during adulthood or early life can cause long-lasting disturbances in the eCB system. These alterations interfere with hypothalamic-pituitary-adrenal axis function and may be involved in lifelong increased fear and anxiety behaviors as well as increased risk for development of post-traumatic stress disorder (PTSD).
Methods: This review focuses on the implications of trauma and significant stressors on eCB functionality and neural pathways, both in adolescence and into adulthood, as well as the current state of testing for CBD efficacy in treating pediatric and adult patients suffering from stress-induced eCB dysregulation. Articles were searched via Pubmed and included studies examining eCB modulation of stress-related disorders in both clinical settings and preclinical models.
Conclusion: Given the potential for lifelong alterations in eCB signaling that can mediate stress responsiveness, consideration of pharmaceutical or nutraceutical agents that impact eCB targets may improve clinical outcomes in stress-related disorders. However, caution may be warranted in utilization of medicinal cannabinoid products that contain delta-9-tetrahydrocannabinol due to pronounced euphorigenic effects and potential to exacerbate stress-related behaviors. Other cannabinoid products, such as cannabidiol (CBD), have shown promise in reducing stress-related behaviors in pre-clinical models. Overall, pre-clinical evidence supports CBD as a potential treatment for stress or anxiety disorders resulting from previously stressful events, particularly by reducing fearful behavior and promoting extinction of contextual fear memories, which are hallmarks of PTSD. However, very limited clinical research has been conducted examining the potential effectiveness of CBD in this regard and should be examined further.
Comparable studies
Other narrative reviews on CBD, most cited first.
Citations in the library
Cited by 2
- Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective. Expert Review of Clinical Pharmacology 2023
- Effects of Cannabinoids on Emotional States and Alcohol Use Among Underrepresented Groups: Moderation by Perceived Discrimination. Human Psychopharmacology: Clinical and Experimental September 1, 2025